Damon Runyon Cancer Research Foundation

Metastatic tumors tend to be less responsive to therapy than primary tumors.

Studying T cell function in microgravity at the International Space Station could eventually lead to new immunotherapies for cancer.

Dr. Su is working to increase the effectiveness and affordability of adoptive T cell therapy.

Research sheds light on KRAS gene mutations and the early development (and possible treatment) of lung cancer.

The toxicity of chemotherapy drugs is tolerated only because there are no better options—in the United States, that is.

Discovery represents an exciting step toward developing new targeted medications for certain types of cancer.

Researchers suggest that aspirin may be especially useful for colorectal cancer prevention for individuals with additional risk factors.

Exploiting naturally occurring mutations may offer a promising approach to treatment.

Damon Runyon Cancer Research Foundation awards $4.8 million to exceptional postdoctoral scientists.

Some cancer cells change behavior when they develop resistance. Researchers identified a new driver in small-cell lung cancer.

There is, of course, no stopping time, but a new study found that there may be a way to slow down the clock.

Damon Runyon emeritus board member Ken Langone was honored at the cancer research foundation’s annual breakfast.

The first of its kind, the LumiSystem combines cutting-edge imaging technology with a novel fluorescent imaging agent.

Damon Runyon launched the one-year intensive cancer research internship program for post-baccalaureate students.

A new tool may provide a less invasive, more accurate means of diagnosis.

Election to membership in the National Academy of Sciences is among the highest honors a scientist can receive.

Physician-scientists are uniquely positioned to conduct research that can improve and prolong the lives of their patients.